Association of Prerandomization Anticoagulant Switching With Bleeding in the Setting of Percutaneous Coronary Intervention (A REPLACE-2 Analysis)

American Journal of Cardiology

Volumn 99, Issue 12, 2007, Pages 1687-1690

  Gibson, C Michael ^a   Ten, Yuli ^a   Murphy, Sabina A ^a   Ciaglo, Lauren N ^a   Southard, Matthew C ^a   Lincoff, A Michael ^b   Waksman, Ron ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SODIUM CHLORIDE; THROMBIN INHIBITOR; TIROFIBAN;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BYPASS SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS;

EID: 34249883553     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.01.053     Document Type: Article

References (5)

1. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
2. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., and Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
3. Waksman R., Wolfram R.M., Torguson R.L., Okubagzi P., Xue Z., Suddath W.O., Satler L.F., and Kent K.M. Switching from enoxaparin to bivalirudin in patients with acute coronary syndromes without ST-segment elevation who undergo percutaneous coronary intervention. Results from SWITCH--a multicenter clinical trial. J Invas Cardiol 18 (2006) 370-375
4. Ferguson J.J., Califf R.M., Antman E.M., Cohen M., Grines C.L., Goodman S., Kereiakes D.J., Langer A., Mahaffey K.W., Nessel C.C., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
5. Caron M.F., and McKendall G.R. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm 60 (2003) 1841-1849